Silexion Therapeutics Announces Groundbreaking Preclinical Results for SIL204, Demonstrating Near-Complete Inhibition of Pan-KRAS Mutations Across Multiple Cancer Types

Reuters · 09/30 13:06

Please log in to view news
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.